Ultragenyx Reports Q4 Earnings Loss

Pharmaceutical company Ultragenyx posts $129 million loss in latest quarter

Published on Feb. 12, 2026

Got story updates? Submit your updates here. ›

Ultragenyx Pharmaceutical Inc. reported a loss of $129 million in its fourth quarter, the company announced on Thursday.

Why it matters

As a major pharmaceutical company, Ultragenyx's quarterly earnings are closely watched by investors and analysts to gauge the overall health and performance of the business.

The details

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on developing and commercializing novel products for rare and ultra-rare diseases, reported a net loss of $129 million for the fourth quarter of its fiscal year.

  • Ultragenyx reported its Q4 earnings on Thursday, February 12, 2026.

The players

Ultragenyx Pharmaceutical Inc.

A biopharmaceutical company that develops and commercializes novel products for rare and ultra-rare diseases.

Got photos? Submit your photos here. ›

The takeaway

Ultragenyx's Q4 loss highlights the challenges pharmaceutical companies face in developing and commercializing treatments for rare diseases, which often require significant investment and time before generating revenue.